Sort   by:  
 Page size 
GenomicsImpact of ELX/TEZ/IVA therapy on the CF airway metagenome
Effect of ELX/TEZ/IVA therapy on CF airway metagenome
PRJEB51171 | ENA
ProteomicsSystemic effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the plasma and serum proteome
Cystic fibrosis (CF), resulting from a dysfunction in the cystic fibrosis transmembrane conductance regulator (CFTR), affects multiple organs through mucus obstruction and differences in secretion. The CFTR modulator drug combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, ETI) has markedly i...
ORGANISM(S): Homo sapiens (Human) 
2026-04-14 | PXD071549 | Pride
Serum Cystic fibrosis Elx/tez/iva Plasma Astral Dda Cftr modulator Dia Hfx Lum/iva Human Sputum Label free 
ProteomicsLongitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis
Rationale: We recently demonstrated that the triple combination CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) improves lung ventilation and airway mucus plugging determined by multiple-breath washout and magnetic resonance imaging in CF patients with at least one F508del alle...
ORGANISM(S): Homo sapiens (Human) 
2023-06-22 | PXD041844 | Pride
Disease Cystic fibrosis Proteome Elexacaftor/tezacaftor/ivacaftor Dda Sputum Label free 
TranscriptomicsRescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers
In cystic fibrosis (CF), loss of CF transmembrane conductance regulator (CFTR)-dependent bicarbonate secretion precipitates the accumulation of viscous mucus in the lumen of respiratory and gastrointestinal epithelial tissues. We investigated whether the combination of elexacaftor (ELX), ivacaftor (...
ORGANISM(S): Homo sapiens 
2021-12-14 | GSE182347 | GEO
UnknownLongitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
Not available
S-EPMC10462202 | biostudies-literature
UnknownImpact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
Not available
S-EPMC10721580 | biostudies-literature
UnknownEfficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
Not available
S-EPMC9746869 | biostudies-literature
UnknownElexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials.
Not available
S-EPMC10798108 | biostudies-literature
UnknownA Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Not available
S-EPMC8483230 | biostudies-literature
UnknownLong-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Not available
S-EPMC10701091 | biostudies-literature
Sort   by:  
 Page size